TG Therapeutics Stock Rises on Strong Briumvi Sales and Raised Guidance
TG Therapeutics (TGTX) boosts 2025 revenue forecast to $616M on strong Briumvi MS drug sales, projects $875M-$900M for 2026, exceeding Wall Street expectations.
/ 1 item
#TGTX↓